ESR1 and cancer: SNP309G was initially found associated with early cancer onset among individuals carrying TP53 germline mutations (Li-Fraumeni syndrome) and spontaneous soft tissue sarcomas as well as estrogen receptor (ER) rich breast cancer [8, 9].